Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Stroke. 2017 Jan 5;48(2):445–451. doi: 10.1161/STROKEAHA.116.014790

Figure 2.

Figure 2

A, Significantly reduced hemoglobin levels in C57Bl6 mice treated with the 12/15-LOX inhibitor ML351 following warfarin and 3h MCAO, compared to vehicle treatment (*p<0.05). B, Less hemorrhage was detected in brain sections of mice treated with ML351 (*p<0.05). C, Infarct size comparison after TTC staining in mice subjected to warfarin plus 3h MCAO showed large infarcts in the vehicle treated mice, which were slightly but significantly reduced following ML351 treatment (*p<0.05). D, Following normalization for infarct size, hemorrhage remained significantly reduced by ML351 treatment (*p<0.05).